EpimAb Biotherapeutics, a global clinical-stage biotechnology company focused on bispecific antibody development, announced that a late-breaking abstract on its novel BCMA-targeted T-cell engager (TCE), EMB-06 (CND106), has been accepted for an oral presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, California (December 7-10, 2024).

This presentation will cover complete Phase I clinical trial results for EMB-06 (CND106), a BCMA-targeting TCE designed for optimized efficacy and safety in patients with relapsed or refractory multiple myeloma. EpimAb recently licensed the exclusive rights to develop and commercialize EMB-06 (CND106) outside Greater China to Candid Therapeutics. Details of the oral presentation are as follows:

Title: A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody EMB-06 in Relapsed or Refractory Multiple Myeloma
Session Date: December 8
Session Time: 10:45 – 11:00AM local time
Location: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Presentation number: 498

Dr. Chengbin Wu, Founder and CEO of EpimAb, stated, “We are delighted to present the complete EMB-06 FIH study results at the ASH Annual Conference. The data underscores EMB-06’s distinct efficacy and safety profile in multiple myeloma patients. This study also validates our TCE technology platform, which we will leverage to advance novel treatments for unmet medical needs.”

About EMB-06

EMB-06 is a novel 2+2 BCMA×CD3 T-cell engaging bispecific antibody developed using EpimAb’s proprietary CD3 panel and bispecific platforms. Notably, this molecule has shown reduced cytokine release in preclinical and clinical studies.

About EpimAb Biotherapeutics Inc

EpimAb Biotherapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of multispecific antibodies. Leveraging its in-house research and technology, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is developing a pipeline of preclinical and clinical assets aimed at improving cancer patient outcomes. For more information, please visit:

IR Contact
Dr. David Gu
+86-21-61951011

BD Contact
Dr. Jason Tang
+86-21-61951014